Method for the rapid identification of covid-19 infection
AssigneesArizona Board of Regents on behalf of Arizona State University, Marv Enterprises, LLC
InventorsQiang Chen, Mitchell S. Felder
Life of this patent
Estimating the term…
Abstract
An embodiment provides a method for identifying Covid-19 in a body fluid of a patient, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody; identifying the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source; and returning the body fluid to the patient. Other aspects are described and claimed.
Claims20
A method for identifying Covid-19 in a body fluid of a patient, comprising:
- removing the body fluid from a patient;
- applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody;
- and
- identifying the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source.
A device for identifying Covid-19 in a body fluid of a patient, comprising:
- a transparent first stage including an inlet for the body fluid and at least one exterior wall defining a treatment chamber;
- a transparent second stage, fluidly connected to the first stage, comprising a removal module and an outlet for the body fluid, wherein the treatment chamber comprises a delivery tube for introducing an antibody into the treatment chamber, wherein the delivery tube comprises a hollow tube including at least one interior wall defining a plurality of holes through which the antibody can be added to the treatment chamber, wherein the treatment is delivered through the hollow tube in counter-current mode with reference to the body fluid;
- and
- at least one sensor to identify the light functional antibody;
- the device being configured to:
- remove the body fluid from a patient;
- apply a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody;
- and
- identify the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source.
A method for identifying Covid-19 in a body fluid of a patient, comprising:
- removing the body fluid from a patient;
- applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody;
- identifying the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source;
- capturing, using an antibody microarray, the antibody-TA complex, wherein the microarray comprises a plurality of the antibody on a transparent solid surface;
- and
- returning the body fluid to the patient.
Dependencies are inferred from the claim text.